Compare PLBL & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBL | TVTX |
|---|---|---|
| Founded | 2021 | N/A |
| Country | Indonesia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | N/A | 2013 |
| Metric | PLBL | TVTX |
|---|---|---|
| Price | $7.14 | $40.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $40.62 |
| AVG Volume (30 Days) | 8.8K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $44.76 |
| Revenue Next Year | N/A | $35.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.60 | $13.88 |
| 52 Week High | $13.48 | $43.31 |
| Indicator | PLBL | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 63.32 |
| Support Level | $5.93 | $32.62 |
| Resistance Level | $9.59 | $42.06 |
| Average True Range (ATR) | 0.97 | 2.03 |
| MACD | -0.03 | 0.16 |
| Stochastic Oscillator | 27.85 | 78.40 |
Polibeli Group Ltd is engaged in goods trading and others to promote the circulation of goods with a focus on making trading easier. The products offered by the company include consumer electronic accessories, household appliances, skincare products, oral-care products, cosmetics products, toys and game products, and health-care products. Geographically, the company derives the majority of its revenue from Japan.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.